Goldman Sachs’s Puma Biotechnology PBYI Stock Holding History

Goldman Sachs’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-74,300	Closed	-$627K	–	5408
2020 Q1	$627K	Buy	+74,300	New	+$722K	﹤0.01%	4072
2017 Q4	–	Sell	-24,000	Closed	-$2.87M	–	6568
2017 Q3	$2.87M	Buy	+24,000	New	+$2.23M	﹤0.01%	3661
2017 Q2	–	Sell	-49,800	Closed	-$1.85M	–	6907
2017 Q1	$1.85M	Buy	+49,800	New	+$1.82M	﹤0.01%	3823
2016 Q2	–	Sell	-57,200	Closed	-$1.68M	–	7184
2016 Q1	$1.68M	Sell	57,200 -82,000	-59%	-$3.71M	﹤0.01%	3643
2015 Q4	$10.9M	Sell	139,200 -24,000	-15%	-$1.88M	﹤0.01%	2188
2015 Q3	$12.3M	Buy	163,200 +143,200	+716%	+$13.5M	﹤0.01%	2092
2015 Q2	$2.33M	Sell	20,000 -15,300	-43%	-$2.77M	﹤0.01%	3689
2015 Q1	$8.34M	Buy	+35,300	New	+$7.55M	﹤0.01%	2449
2014 Q4	–	Sell	-12,500	Closed	-$2.98M	–	7263
2014 Q3	$2.98M	Sell	12,500 -36,900	-75%	-$7.58M	﹤0.01%	3538
2014 Q2	$3.26M	Buy	+49,400	New	+$3.51M	﹤0.01%	3477

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Goldman Sachs's PBYI Position: Q1 2026 in Review

Goldman Sachs reduced its Puma Biotechnology (PBYI) stake by 16% in Q1 2026, selling an estimated $801K and leaving 669,719 shares worth $4.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3858.

Goldman Sachs first reported a position in PBYI in Q2 2013 and has held it in 52 quarters since. The position peaked at $59.7M in Q3 2017. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

Goldman Sachs held 669,719 shares of Puma Biotechnology worth $4.28M as of Q1 2026.
Goldman Sachs sold 124,243 Puma Biotechnology shares in Q1 2026, an estimated $801K.
Puma Biotechnology made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3858 holding.
Goldman Sachs first reported a position in Puma Biotechnology in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Puma Biotechnology position peaked at $59.7M in Q3 2017.
157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.